Feds To Propose Boost In Marijuana Quota For Research, Cut To Opioid Manufacturing Limit

Federal drug enforcement officials want to boost the amount of marijuana that can be legally produced for research in the United States while cutting the number of opioids that can be manufactured in the country.

The U.S. Drug Enforcement Administration said in a press release Wednesday that it will propose to boost the amount of marijuana produced for research next year by nearly a third, to 3,200 kilograms. That would be almost triple the amount produced in 2018.

The agency said that over the last two years the number of people registered by the DEA to conduct research with marijuana, marijuana extracts and derivatives has increased by more than 40%, making the increase in production necessary.

The DEA said it will at the same time propose a reduction in the manufacturing of five opioids, including fentanyl, a dangerous and addictive drug that has been blamed for a high number of deaths from misuse. The agency wants production of the drug cut by 31%.

The proposal will also call for cutting production of the painkiller hydrocodone by 19%, hydromorphone by 25%, oxycodone by 9% and oxymorphone by 55 %. Combined with morphine, the proposed quota would be a 53 percent decrease in the amount of allowable production of those opioids since 2016, the agency said.

The proposal will be published Thursday in the Federal Register.

Click here for more information about the upcoming Benzinga Cannabis Capital Conference Oct. 22-23 in Chicago.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisGovernmentNewsRegulationsHealth CareMarketsGeneralDrug Enforcement AdministrationmarijuanaOpioids
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!
CCC-Oct-24-Banner-1

Click on the image for more info.

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry?

Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. 

Get your tickets now before prices surge by following this link.